Summary
For muscle-invasive bladder cancer (MIBC), there are no tissue biomarkers in clinical use that identify patients sensitive or resistant to neoadjuvant chemotherapy. The present study investigates how molecular subtypes impact pathological response and survival in 149 patients receiving preoperative cisplatin-based chemotherapy. Tumor classification was performed by transcriptomic profiling and by a 13-marker immunostaining panel. Furthermore, we explored differential gene expression and chemotherapy response beyond molecular subtypes. Tumors with Genomically Unstable (GU) and Urothelial-like (Uro) subtypes had higher proportions of pathological response and superior survival outcomes as compared to the Basal-Squamous (Ba/Sq) subtype following neoadjuvant chemotherapy and radical cystectomy. Based on our findings, we suggest that urothelial cancer of the luminal-like GU- and Uro-subtypes are more responsive to cisplatin-based chemotherapy. We also found the gene coding for osteopontin (SPP1) to display a subtype-dependent effect on chemotherapy response, confirmed at the protein level by immunohistochemistry. Combined analyses of second-generation, subtype-specific biomarkers may be an additional way forward to develop a more precision-based treatment approach for neoadjuvant chemotherapy in MIBC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Swedish Cancer Society (grant numbers CAN 2017/278 and 2020/0709), Lund Medical Faculty (ALF), The Crafoord Foundation (ref 20130591 and 20140532), Skane University Hospital Foundation, Torsten Gester Foundation, Gyllenstierna Krapperups Foundation (KR2017-0031, KR2018-0050, KR2019-0019), Sten K Johnsson Foundation, Sigurd and Elsa Golje Foundation (LA2017-0222), Magnus Bergvall Foundation, Maud and Birger Gustavsson Foundation, Malmo General Hospital Cancer Foundation, Royal Physiographic Society of Lund, Skane County Council Research and Development Foundation, Gunnar Nilsson Cancer Foundation, Gosta Jonsson Research Foundation, Foundation for Urological Research (Ove and Carin Carlsson bladder cancer donation), and Hillevi Fries Research Fund. The funding sources had no role in the study design, data analyses, interpretation of the results, or writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Research Ethics Board of Lund University (2012/22; 2013/264; 2017/37)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Gene expression data is available via Gene Expression Omnibus with the accession number GSE169455.
